Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
Sponsor: Sanofi
Summary
The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Official title: A Phase 4, Open-label, Single-arm Clinical Study to Describe Safety and Efficacy Outcomes Associated With the Use of Nirsevimab in Neonates and Infants Born During or Entering Their First Respiratory Syncytial Virus (RSV) Season and in Children up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Key Details
Gender
All
Age Range
0 Months - 24 Months
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2025-07-31
Completion Date
2026-06-30
Last Updated
2026-03-23
Healthy Volunteers
Yes
Conditions
Interventions
Nirsevimab
Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular
Locations (7)
Investigational Site Number : 3560002
Bengaluru, India
Investigational Site Number : 3560008
Jaipur, India
Investigational Site Number : 3560003
Kolkata, India
Investigational Site Number : 3560007
Nagpur, India
Investigational Site Number : 3560001
New Delhi, India
Investigational Site Number : 3560004
Pune, India
Investigational Site Number : 3560006
Vizianagaram, India